Daniel Hertz, PharmD, PhD
College of Pharmacy
428 Church St
Ann Arbor, MI 48109-1065
Dan Hertz joined the Department of Clinical Pharmacy in the College of Pharmacy in April 2013. He received his PharmD from the Ernest Mario School of Pharmacy at Rutgers University and his PhD in pharmaceutical sciences from the University of North Carolina Eshelman School of Pharmacy.
Interested in developing tools for individualizing cancer treatment, his current work focuses on the optimal use of paclitaxel in breast cancer. The approaches being developed include identifying an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity, particularly as it relates to neuropathy. Hertz is also interested in understanding the influence of patient genetics on cancer treatment outcomes. He uses several approaches to discover and validate the effect of common variants on drug exposure or patient sensitivity to toxicity. Much of this work is conducted through his membership in oncology cooperative groups, which provide access to sufficiently large patient cohorts for definitive analyses.
Developing tools for individualizing cancer treatments
Understanding the role of patient genetics in treatment outcomes
Translating genetic associations into clinical practice to improve patient care
Hertz DL, McShane LM, Hayes DF, Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. J Clin Oncol. 2022;24(10):02209. doi: 10.1200/JCO.21.02209. [Epub ahead of print] PubMed PMID: 35324346.
Chen CS, Kim J, Garg N, Guntupalli H, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, Hertz DL. Chemotherapy-induced peripheral neuropathy detection via smartphone app: a cross-sectional pilot study. JMIR Mhealth Uhealth 2021;9(7):e27502 doi: 10.2196/27502
Hertz DL, Kidwell KM, Vangipuram K*, Li F, Pai MP, Burness ML, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Smith EM, Henry NL. Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res. 2018 Apr 27. pii: clincanres.0656.2018. doi: 10.1158/1078-0432.CCR-18-0656. [Epub ahead of print] PubMed PMID: 29703818.
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech L, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev. 2021 Jun 9;99:102241. doi: 10.1016/j.ctrv.2021.102241. [Epub ahead of print] Review. PubMed PMID: 34174668.
Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens ST, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.
Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013 Jun;24(6):1472-8. PMID: 23413280, PMCID: PMC3660078
Hertz DL, Ramsey LB, Gopalakrishnan M, Leeder JS, Van Driest SL. Mini-Review: Analysis Approaches to Identify Pharmacogenetic Associations with Pharmacodynamics. . Clin Pharmacol Ther. 2021 May 27;. doi: 10.1002/cpt.2312. [Epub ahead of print] Review. PubMed PMID: 34043820.